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Since 2007, the Branislav “Brano” Radovancevic Heart Failure Forum has been
held annually to provide a venue for experts to present and discuss “Innovations
and New Treatment Strategies in Heart Failure.” Clinicians and researchers gather
yearly in a different Eastern European city to discuss the latest in heart failure
diagnostics and therapeutics. The forum was postponed in 2020 due to the
COVID-19 pandemic and then resumed in September of 2021 in Graz, Austria. It
was attended by over 75 faculty from 13 countries. Due to the ongoing pandemic,
13 presentations were given virtually. Throughout the forum, 17 separate sessions
focused on challenges and solutions related to mechanical circulatory support and
heart transplantation. In this special issue of The VAD Journal, a summary of
conference highlights from available presentations is presented.
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Failure Management: COVID-19 Effects and Consequences
Advanced Heart Failure Surgical Management: Impact of the COVID
Pandemic
Within nine months of COVID-19 being identified in Wuhan, China, the virus
spread worldwide, causing more deaths than HIV, malaria, influenza, cholera, and
measles combined. At ten months, there were over 40 million cases worldwide.
The early reported mortality in heart and lung transplant recipients was 20% 30%, but more recently, the rate is estimated to be 15%.1 Vaccinated transplant
patients develop antibodies at much lower titers than the general population. Risk
factors for death in the transplant population include age > 60 years and threedrug immunosuppression.1 The major causes of death in transplant patients with
COVID-19 are secondary infection, pulmonary failure, and multiple organ failure.
The experience of COVID-19 in pediatric patients is very different than in adults. In
a study involving pediatric transplant patients, all were screened for COVID-19,
and 21% were positive.2 Of those positive for COVID-19, 55% were asymptomatic,
and there was no mortality. The Pediatric Heart Transplant Society confirmed
these findings and reported that COVID-19 in pediatric heart transplant patients is
relatively benign. Compared to 2019, there was a 20% reduction in the number of
left ventricular assist devices (LVADs) implanted in 2020, and this decrease
persisted in 2021. LVAD-supported patients are more susceptible to severe
COVID-19, with an estimated mortality of 20% - 25%.

COVID-19: Reversal of Inflammation
The timing of inflammation defines the importance and effectiveness of
immunosuppression. Early, aggressive immunosuppression during viral replication
leads to more severe COVID-19 symptoms. The best time to actively suppress the
inflammatory process is once the virus has triggered the inflammatory cascade.
Immune checkpoint inhibitors have transformed how cancer is treated by
unleashing the immune system. When the immune system is activated, there are
regulatory pathways that decrease the state of inflammation. Immune checkpoint
inhibitors with dual agents increase the risk of cardiac immune-related adverse
events. In an animal model of heart failure, immune checkpoint inhibitors
increased mortality.3 A way to modulate the inflammatory response in this setting
is with Cannabis sativa. A pharmaceutical form of cannabidiol (CBD) is being
developed from cannabis for its ability to decrease inflammation. CBD reduces
cellular hypertrophy in a dose-dependent manner and attenuates heart failureinduced left ventricular (LV) dysfunction. There is now an ongoing trial studying
CBD in patients positive for COVID-19 with a prior history or significant risk factors
for cardiovascular disease with the hope that this treatment will reduce the
inflammatory cascade that occurs in COVID-19.

EUROMACS and COVID-19
During the COVID-19 pandemic, there was a significant decline in heart failure
hospitalizations. In the United Kingdom the decline was 27%, and in Germany, it
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was 27%. There was an increase in heart failure mortality for hospitalized patients.
Withdrawal from guideline-directed medical therapy was associated with increased
mortality. Patients with chronic heart failure were more prone to develop acute
heart failure, and 40% of cases were de novo. At one center in Germany, there
was a sharp increase in the use of Impella devices due to both the pandemic and
reimbursement changes. There was no increase in the use of extracorporeal life
support (ECLS) or durable LVADs in INTERMACS profile 1 patients. In Germany,
there was a decline in the use of durable mechanical circulatory support (MCS,12%) and heart transplantation (-13%). The EUROMACS database has recorded
74 patients supported by an LVAD with COVID-19. Of these patients, 49 (66%)
required hospitalization with 11 cases of acute heart failure. The in-hospital
mortality was 28.6% with the most common cause of death being multiple organ
failure, respiratory failure, and cerebrovascular events. Thromboembolic risk
during LVAD support remains low, even in patients with COVID-19.

Update on Drug Therapy of Heart Failure
The 2021 European Society of Cardiology (ESC) has introduced new guidelines
for diagnosing and treating acute and chronic heart failure.4 The ESC has a new
algorithm for the management of heart failure with reduced ejection fraction
(HFrEF) that now includes the use of SGLT2 inhibitors. Subsequently, a study has,
for the first time, demonstrated the positive effects of empagliflozin on the
treatment of heart failure with preserved ejection fraction. There was an
improvement in the cumulative incidence of mortality of 21%. Several treatments
can be used for the prevention of heart failure. Patients with Stage A heart failure
should receive treatment for hypertension and dyslipidemia, stop nicotine and
alcohol, and increase exercise. In patients with Stage B structural heart failure, the
addition of ACE inhibitors and beta-blocker therapy is recommended. Medications
shown to benefit patients with structural heart disease include Enalapril, Ramipril,
Simvastatin, and Clopidogrel. Statin therapy has lipid and non-lipid mechanisms
for protection against heart failure and is encouraged to be used. RNA-related
drugs have many possibilities including vaccines and Patisiran and Inclisiran to
help control LDL cholesterol.

Acute Mechanical Circulatory Support – How to Manage
During Pandemics
COVID-19 ECMO: What Worked and What Didn’t
The effectiveness of extracorporeal membrane oxygenation (ECMO) was unknown
at the start of the COVID-19 pandemic. Historically, the effectiveness of ECMO
therapy was approximately 40% for all causes of acute respiratory distress
syndrome (ARDS). China's early results on using ECMO for COVID-19 ARDS
were dismal.5 In a study out of France on 83 patients supported with ECMO for
COVID-19, 34 (41%) returned home, and 30 (36%) died.6 The remaining patients
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(23%) were still hospitalized.6 In a study of 40 patients where ECMO was applied
early (13.8 days), the survival rate was 73%.7 At the Oklahoma Shock and ECMO
network, 84 patients with COVID-19 ARDS were supported by ECMO. During the
pandemic, the acceptance rate for ECMO therapy was about 1 patient in every 12
referrals. Due to limitations in hospital capacity, the inclusion criteria became
progressively stricter. A study of 61 patients supported with ECMO in Oklahoma
reported that 22 (40%) died on support, 36 (59%) were weaned from support, and
32 (52%) were discharged. No anticoagulation therapy was used in 28 (46%)
patients, and 13 (21%) were extubated while on ECMO support. The EOLIA trial
entry criteria are widely accepted for COVID-19 patients requiring veno-venous (VV) ECMO.8 The survival rate of V-V ECMO in COVID-19 patients is similar to nonCOVID-19 patients. The duration of V-V ECMO is longer in COVID-19 compared
to non-COVID-19 cases. There were more bleeding complications than strokes in
this population. Of the entire population of hospitalized patients with COVID-19,
80% are unvaccinated.

ECMO Anticoagulation Problems in COVID-19 Patients
Many hospitals remain overwhelmed with COVID-19 cases that require ECMO and
ventilator support. Early pandemic data demonstrated that patients who develop
pulmonary failure with cytokine storm have significant inflammation with the
downregulation of lymphocytes.9 The coagulation system is affected by these
changes. A recent report showed that there is a breakdown of endothelial cells
from the COVID-19 infection which causes a platelet – von Willebrand factor
interaction.10 In a comparison between patients with COVID-19 and controls, there
is a significant increase in fibrinogen and von Willebrand factor antigen with
thrombocytopenia and lymphopenia in the infected patients.11 Coagulation factors
are affected by the severity of the COVID-19 infection. The phases of ECMO
therapy in patients with COVID-19 begin with an initial inflammatory insult,
followed by organ recovery and endothelial healing. There are then secondary
ECMO complications, including coagulopathy. In the initial inflammatory phase of
COVID-19, there is an increase in fibrinogen, von Willebrand Factor antigen, and
D-dimer, and a decrease in platelets and lymphocytes. Endothelial damage in
combination with dysregulated primary hemostasis may lead to severe thrombosis
in the arterial and venous circulations. Life-threatening complications of this
inflammatory effect may include thrombocytopenic thrombosis, cerebral
hemorrhage or infarction, cerebral venous sinus thrombosis, or pulmonary
embolism. Unusually long ECMO runtimes are associated with COVID-19
respiratory failure which leads to an increase in secondary ECMO complications.

Impella 5.0 as a Bridge to LVAD Therapy
Recent guidelines have established short-term MCS to be indicated for patients
with INTERMACS profiles of 1 or 2 as a bridge-to-decision or bridge-to-transplant.4
The rationale of short-term MCS is to protect the patient from multi-organ failure
and reverse cardiogenic shock until a more definitive therapy can be determined.
There are different choices of MCS systems, which are determined by the need to
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stabilize hemodynamics and reverse shock to maximize the chance for cardiac
and end-organ recovery. In an analysis of pressure-volume loops comparing
ECMO with Impella (Abiomed) support, ECMO reversed cardiogenic shock.
However, ECMO does not unload the LV, whereas Impella devices do. The
Impella device provides the most physiologic support to the LV, but the
disadvantage is that it can only provide isolated LV support. In patients with
reasonable LV function and sufficient oxygenation, isolated LV support is suitable.
For those requiring right-sided or pulmonary support, ECMO plus Impella support
may be used. The use of the Impella as a bridge-to-decision during acute,
decompensated, advanced heart failure is a common approach used today.12 Use
of the Impella with veno-arterial (V-A) ECMO improves survival of patients with
cardiogenic shock.13 The type of short-term MCS should be individualized to the
patient’s condition while considering LV, right ventricular (RV), and pulmonary
function.

LVAD Complications
Upgrading to Impella 5.5: An innovative Technique with Uninterrupted
Support
The Impella CP axial flow pump (Abiomed) is inserted percutaneously and can
provide up to 3.5 L/min of support under ideal conditions. The Impella 5.5
(Abiomed) is a larger pump inserted through a graft on the axillary artery and can
provide up to 5.5 L/min of cardiac support. For some patients requiring a higher
level of cardiac output support, the CP device is exchanged for a 5.5 device. The
usual approach for the exchange is to pass a 0.18 wire into the LV, turn off the CP
device and remove it, advance the 5.5 device over the wire, remove the wire, and
start the pump. During this exchange procedure, there is a period of no support,
which some patients do not tolerate well. A technique for uninterrupted support
involves passing the Impella 5.5 under fluoroscopic guidance into the LV while the
CP device is still functioning. After the position of the 5.5 is confirmed, the wire is
removed, and support is transitioned from the CP to the 5.5. Crossing the aortic
valve with the wire is easier when the CP is in place and functioning.
Hemodynamic instability is avoided during the exchange, and there have not been
procedural complications.

HVAD Exchange to HeartMate 3? Pro/Con
The Heartware Ventircular Assist Device (HVAD, Medtronic) has had more Food
and Drug Administration recalls than any other device in history. In the
MOMENTUM trial, the survival rate at 24 months was 78% for the HeartMate 3
(HM3) compared to 56% for the HeartMate II (HMII).14 In the CLEAR LVAD study,
the HM3 survival rate at 12 months was 85% while the survival for all other
LVADs, mostly HVAD, was only 73%.15 However, in a study comparing short-term
outcomes between those supported by the HM3 and HVAD, there was no
difference in survival at 3 months, but there were fewer complications in the HM3
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patients.16 During a median follow-up of 15.3 months (range: 0-30 months), 23
(29.1%) and 19 (24.1%) patients died in the HVAD and HM3 groups, respectively.
A systematic review of LVAD exchange showed that there are serious
complications including RV failure, renal failure, and death.17 The study also
observed that following device exchange, the HM3 is associated with a lower risk
of stroke and higher survival than the HVAD. The 30-day mortality following
exchange is approximately 10%. In addition, there is a risk of right heart failure
(RHF). The reported survival difference after 3-6 months is 5%.

Cardiorenal Syndrome Treatment with Assist Devices: Second Heart
Assist Device
Numerous factors play a significant role in cardiorenal syndrome. The most
common factor is acute and chronic hemodynamic compromise that is manifested
by low cardiac output and blood pressure causing kidney function to deteriorate
over time. Non-hemodynamic factors include neural, an imbalance of oxygen and
nitric oxide production, humoral, and inflammatory. There have been more than 24
failed drug clinical trials for treating congestive heart failure and cardiorenal
syndrome. There is a need for a mechanical solution to treat this problem. There
are a variety of temporary, percutaneous MCS systems available today for the
treatment of acute heart failure, but they are not optimal for treating cardiorenal
syndrome. There are new MCS devices that are positioned in the descending
aorta and designed to increase renal blood flow by increasing aortic flow. The
rationale for the placement of these devices in the descending thoracic aorta is
that they avoid crossing the aortic valve, minimize the risk of stroke, are close to
the kidneys, and easy to insert. There is a pressure drop across these pumps, but
the amount of blood flow generated in the aorta is unknown.

Challenges in Mechanical Circulatory Support
Insights into Interventricular Interactions in LVAD Patients
The changes in central venous pressure (CVP) and RV hemodynamics in patients
supported by the HM3 during a ramp speed test were studied. As the pump speed
is increased, the CVP does not change; however, the end-diastolic and endsystolic volumes increase.18 This data questions the RV and LV interdependence.
Interventricular interaction is the influence of LV function on RV function and vice
versa. This is often cited in the pathogenesis of post-LVAD RV failure.19The
components of interventricular interactions are parallel and serial interactions.
Because both ventricles share a septum, changes on one side will affect the other
side. Testing involves conductance volumetry for pressure-volume analysis in the
RV during ramped speed studies. Patterns of interaction are identified by
observing changes in the pressure-volume loop with changes in LVAD speed.
Changes in pump speed do not change the pressure-volume loop in the RV in
most patients; however, other patients show some diastolic pressure interaction.
RV systolic interactions are observed in a few patients. Interventricular interactions
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manifest heterogeneously. Systolic interactions result in diminished RV systolic
function. Diastolic interactions render the RV more compliant and improve
function. The balance between these opposing forces and the net effect of
interventricular interactions is also variable and patient-specific.

Temporary MCS in Right Heart Failure
The Impella RP device is inserted through the right femoral vein and pumps 2-4
L/min of blood from the right heart to the pulmonary artery. Patients must be
immobilized as the right femoral vein is required for insertion. A surgical right
ventricular assist device (RVAD) such as Rotoflow, TandemHeart, or CentriMag
provides high flow and is inexpensive, and the pulmonary valve is protected. The
disadvantages of this type of support are the requirement for an external graft and
LVAD explantation and heart transplantation are more difficult. The TandemHeart
can be used with a dual cannula technique with the inflow positioned in the right
atrium and the outflow in the pulmonary artery. The advantages are that ECMO
may be used, and it is inserted percutaneously; however, venous access is
required, and the pulmonary valve may be distorted. The Protek Duo, a single dual
lumen cannula inserted through the internal jugular vein, may be used with
Rotoflow, TandemHeart, or CentriMag pumps and can provide 2-4 L/m of support.
This cannula is inserted percutaneously, patients can be mobile, and ECMO can
be used, but the right internal jugular vein is required for insertion. Right heart
support can also be provided using V-A ECMO. A RHF treatment algorithm gives
guidance on the diagnosis of RV failure and the selection of the various methods
of support.20 Use of RVAD support prophylactically with LVAD implantation is
important to prevent acute decompensation.

Late Right Heart Failure
The hydraulic impedance of the RV is less than the LV, and the pressure is lower
with a continuous decrease.21 The RV volume and ejection fraction are sensitive to
acute changes in afterload. RV function is dependent on LV function because the
LV serves as an anchor to the RV.22 The RV is coupled to a low hydraulic
impedance with volumes and ejection sensitized to changes in afterload. RV
function is uncoupled when RV function is less than its load. RV output and
generation of RV pressure are dependent on LV function. Interventricular
interdependence is when the volume and pressure loading of one ventricle
impacts the other. LV unloading de-pressurizes the LV, and depending on the
Starling point, LV function could decrease or increase. LV unloading may depressurize the RV and improve its function. The unpredictable nature of LVAD
implantation indicates that the post-implant RV function is determined by preimplant conditions. The RV has a tremendous capacity to recover function.
Consequently, if the RV needs a lot of support after LVAD implantation, the
outcome is usually poor. Ten percent of patients with LVADs will develop late
RHF. For patients with late RHF, adverse events such as gastrointestinal bleeding
and stroke are increased.
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Prediction of Right Heart Failure in LVAD Patients
RHF is a frequent post-LVAD implantation complication that contributes to early
morbidity and mortality. Prediction and recognition of RHF can help identify highrisk patients, improve patient selection, allow timely intervention, and improve
outcomes. Most RHF prediction scores have been derived from small populations
and heterogenous cohorts and were done in the earlier generation LVADs.
Although prediction models have strong performance in study cohorts, they only
have modest performance in general cohorts. Predicting RHF following LVAD
implantation is difficult due to the complex and heterogeneous nature of postLVAD RHF. Novel machine learning models may improve prediction in the future.
The EUROMACS-RHF risk score is a simple bedside prediction score that
outperforms other known models.23 Accurate RHF prediction may help to optimize
perioperative treatment strategies. Future studies on RHF prediction should
determine if these models will improve survival and shorten ICU stays. Better RHF
prediction can improve patient selection and shared decision making, more
intensive RHF treatment pre-LVAD, guide preemptive use of RVADs, and
alternative surgical approaches.

Treatment of Biventricular Failure
For patients with anatomic abnormalities or a high risk of RV or biventricular
failure, implantation with a total artificial heart (TAH) or biventricular support
(BiVAD) is an acceptable option. The TAH is indicated in patients with clinical
conditions or anatomical factors unsuitable for LVAD support. Most of these
patients have an INTERMACS profile of 1 or 2, whereas heart transplant recipients
typically have an INTERMACS profile of 3 or greater. There are several indications
for BiVAD support; however, most patients who receive the support have
advanced heart failure and cannot undergo a transplant procedure. Transplant
ineligibility diagnoses include cardiac tumors, severe giant cell myocarditis,
primary graft failure, and failing Fontan. Thus, TAH with cardiectomy and BiVAD
with preservation of the natural heart are alternatives for this subset of patients.
BiVAD options include implantation with two VADs, with the preferred implant at
the RV or right atrium. Of note, BiVAD support with both HMII and HM3 is off-label.
The SynCardia TAH is the only approved device for long-term BiVAD support.
Survival in staged BiVAD support is poor and should be avoided. The timing for
the implantation of a TAH or BiVAD is crucial and should be as soon as possible.
Successful bridge to transplant occurs in approximately 50% of patients supported
by the SynCardia TAH, and post-transplant survival is comparable to those with
BiVAD support.
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Challenges in Heart Failure Interventions
Cardiac Resynchronization Therapy in Heart Failure
Cardiac resynchronization therapy (CRT) is an established therapy for heart failure
patients, especially those with left bundle branch block. Despite regional
differences, CRT is widely available and should be strictly incorporated into the
management of heart failure to reduce the need for more advanced, less available
therapies, such as heart transplantation and MCS. The response rate to CRT
could be improved by better patient selection and procedural guidance. There is a
lack of evidence demonstrating the efficacy of a CRT upgrade; however, the
results of a large, randomized study (Budapest-CRT) will be published next
year.24,25 Individual risk stratification for predicting the long-term outcome of CRT is
essential. State-of-the-art machine learning methods may help answer the many
questions regarding the use of CRT.26

Percutaneous Options for Tricuspid and Pulmonic Valves
Tricuspid annular dilation results in poor coaptation of the valve and severe
tricuspid regurgitation. The 2020 ACC/AHA guidelines for managing patients with
valvular heart disease provide very little information on treating tricuspid valve
abnormalities.27 Valvular heart disease is classified as A, B, C, or D based on
symptoms, anatomy, and severity of valve dysfunction. Symptomatic, isolated
tricuspid regurgitation may be treated with surgical intervention to reduce
symptoms, prevent right heart dysfunction and end-organ damage, and reduce
recurrent hospitalizations. There is little published information on the surgical
treatment of isolated, severe tricuspid regurgitation. Echocardiographic evaluation
is used to assess the severity of valvular dysfunction and for candidate selection
for percutaneous treatment of valve dysfunction. Because the anatomy is
heterogeneous in these patients, various devices may be applied. Device selection
is based on the etiologic mechanism involved in tricuspid regurgitation and the
specific anatomic features. The percutaneous option includes procedures for
coaptation, annuloplasty, and transcatheter valves. The Melody Transcatheter
Pulmonary Valve (Medtronic) is a stented device that can be placed to dilate the
pulmonary valve in cases of severe stenosis. Edwards Lifesciences’ Sapien valves
can be implanted in the RV outflow tract to treat pulmonary valve abnormalities.

Potential Role of Smart Materials in Heart Failure Surgery
The alternatives to heart transplantation include biological (cell therapy and tissue
engineering) and mechanical (assist devices and polymers) options. The biological
alternatives have not advanced much in recent years; however, MCS has made
significant progress. Although, there are remaining challenges with MCS. The ideal
mechanical assist device would be pulsatile and has no blood-contacting surfaces.
Existing cardiac compression devices have the disadvantage of being
pneumatically powered. A novel concept is the application of a polymer that
contracts with electrical stimulation and could be placed on a portion of the heart
or entirely around the heart.28 The biological surfaces and pulsatility can be
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preserved using electrically contractile polymers. Unfortunately, the electrical
efficacy of high-power polymers results in temperatures too high to be used with
the heart. Coating the polymer with silicone helps to reduce this heat. Experiments
on sheep hearts have demonstrated that high heart rates and pressure as high as
140 mmHg can be achieved. Another novel approach uses carbon nanotubes that
can generate electricity when stretched mechanically. Electrical stimulation can
cause carbon nanotubes to contract, which has the potential to charge batteries
and store power. Thus, it could be used as a pacemaker.

Hot Topics in Heart Transplantation
Long-term Survival after Heart Transplant: Quality of Life
Quality of life (QOL) has been defined as “the functional effect of an illness and its
consequent therapy upon a patient, as perceived by the patient.”29 Data from the
International Society of Heart Lung Transplantation show a steady improvement in
survival after a heart transplant, and survivors at 5 to 10 years have a QOL that is
positive and stable. However, evaluating QOL is complex and requires evaluation
of multiple domains. A psychosocial outcomes workgroup of the Nursing and
Social Sciences Council established recommendations for assessing QOL
following a heart transplant.30 The numerous domains that contribute to QOL are
the transplant, physical functioning, psychological, behavioral, and social. A multicenter study of 555 patients assessing multiple domains out to ten years posttransplant showed very good QOL.29 Some of the predictors of a worse QOL are
depression, fatigue, dermatologic distress, hopelessness, coronary artery
vasculopathy (CAV), degree of family stress, transplant event, and uncertainty.
QOL is important for transplant recipients, their friends and family, and their
healthcare providers. Although QOL has been suggested as a performance metric
following transplantation, the complexity and resulting data burden limit its
feasibility. Interventions to enhance predictors of good QOL and minimize the
effects of factors that decrease QOL are crucial to improving post-transplant QOL.

Clinicopathological Correlates of Early and Late Complications
Following Cardiac Transplantation
This study aimed to correlate clinical and pathological findings in patients with a
complicated or truncated course leading to reintervention or death following
orthotopic heart transplantation. The study included patients treated for heart
failure at a single institution between October 2012 and July 2021. The study
cohort comprised 51 patients with short-term or long-term complications and a
truncated course. Patients were allocated to one of three groups based upon their
time from transplant to end-point (death/re-transplant). Group 1 (< 30 days) had 12
patients; Group 2 (30 days to 1 year) had 13; and Group 3 (> 1 year) had 26.
Pathologic findings from LV cores, explanted native hearts, post-transplant
endomyocardial biopsies and explanted hearts at autopsy were reviewed. The
study's results documented three distinct clinicopathological patterns related to the
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duration of the post-transplant course. A fatal outcome at < 30 days is
characterized clinically by early primary graft dysfunction and is associated with
endomyocardial biopsy evidence of acute ischemic damage without acute cellular
rejection (ACR) or antibody-mediated rejection (AMR). The fatal outcome between
30 days and 1 year is characterized by graft dysfunction with evidence of ischemic
damage often combined with ACR and AMR. Fatal outcomes after 1 year are often
due to non-cardiac causes; however, some patients have a combination of graft
dysfunction.

Heart Transplantation Is and Will Be the Gold Standard
The current standard therapies for HFrEF are beta-blockers, angiotensinconverting enzyme inhibitors/angiotensin receptor blockers, devices (ICD, others),
and sodium-glucose cotransporter-2 inhibitors. Part of this therapy regimen can
improve QOL to a point. The treatment modalities for end-stage HFrEF are MCS,
heart transplantation, and compassionate end-of-life care. MCS requires a
percutaneous connection, external power and control, and no submersion in water.
Heart transplantation requires medications, regular medical contact, and an
increased risk of cancer and infection. Compassionate care varies in regimen but
would involve stopping all devices and medications. The QOL following
transplantation is mostly very good, which is documented by the ISHLT through a
survey of patients after transplantation. The functional status of heart transplant
recipients measured by the Karnofsky score shows excellent results out to 5-years
after transplant. Interestingly, self-reported employment status after transplant
indicates that many patients are not working. However, in large part because of
survival, heart transplantation remains the gold standard for the treatment of endstage heart failure.

Dr. David O. Taylor Memorial Lecture
Man of Unprecedented Intelligence, Humility, and Kindness
David Taylor was born May 22, 1959, and was raised in Artesia, New Mexico.
David matriculated from Baylor University to the University of New Mexico School
of Medicine. He completed Internal Medicine Residency, Cardiology Fellowship,
and Heart Failure Transplant Fellowships at the Medical College of Virginia (MCV).
At MCV, David was under the mentorship of Dr. Michael Hess who inspired him to
pursue a career in heart failure and transplantation. David’s career in heart failure
began in 1991 at the age of 34 years when he became the Medical Director of the
heart transplant program at the VA Medical Center in Salt Lake City. At the age of
42, David achieved the appointment of Professor of Medicine at the University of
Utah. In 2001 David moved to the Cleveland Clinic and was the Director of the
Heart Failure/Transplantation Fellowship Program from 2004 to 2017. David was
frequently honored as the Teacher of the Year at the Cleveland Clinic. His
academic achievements include over 200 published research papers, review
articles and book chapters, and numerous lectures around the world. In addition to
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his clinical and academic responsibilities, David devoted much of his time to the
community and served at the ISHLT president from 2012 to 2013. After his
Presidency at ISHLT his commitment to the society continued with activities on
multiple committees, task forces and the Journal of Heart Lung Transplantation. In
2021, the ISHLT awarded Dr. Taylor with its highest honor, the Lifetime
Achievement Award. David was a Master of Work-life balance and was profoundly
dedicated to his family. David participated in many of the Brano Heart Failure
Forum meetings and was a very active presenter and discussant. Thousands of
patients are indebted to David for saving their lives and he will be remembered as
a legendary educator, valued mentor, skilled physician, and amazing colleague.

The Cardiac iBox
There is an unmet need for a predictive model to better identify risks and
outcomes. The Cardiac iBox system has the potential for risk stratification by
machine learning and algorithmic decision-making. Algorithms can synthesize
multiple variables and quantify risk. System inputs include noninvasive biomarkers,
gene expression, histology, clinical presentation, and immunology. Advanced
statistical analysis includes collinearities, performance, discrimination, calibration,
validation, competing risk, and adaptability which culminate into diagnostic risk
prediction. The study “Identification and Characterization of Trajectories of Cardiac
Allograft Vasculopathy after Heart Transplantation” used multiple donor and
recipient characteristics from 1301 transplanted patients using precision medicine
to predict outcomes.31 Analysis of 1-year data was used to predict outcomes at 5
and 10 years after transplant. The statistical analysis used was a latent class
mixed model (LCMM) with an unsupervised method adapted to repeated
measurements allowing the detection of underlying groups in longitudinal data.
Statistical parameters are tested to obtain the best profiles of CAV trajectories.
LCMM associates logistic regression and a mixed model. Patients are given
likelihoods of belonging to latent classes. Baseline characteristics showed that the
average donor age in the United States was significantly less than in Europe,
which explains why there was less donor-transmitted disease in US patients.
Multiple studies have shown that older donors have more CAV. Of the 4
trajectories of CAV, latent class 1 will do well and doesn’t need annual coronary
angiograms, whereas latent class 4 has some CAV at 1-year and have a poor
trajectory that should lead to adjustments in therapy. A higher percentage of
patients with younger donors are in latent class 1 vs. latent class 4 having
significantly older donors. Multivariate analysis showed that there are donor,
recipient, and immunologic risk factors for developing CAV. There is now an online
calculator that will provide a personalized prediction of CAV trajectory. Future use
of the Cardiac iBox includes donor selection, response to treatment, and treatment
recommendations.
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Challenges in Heart Transplantation
Antibody-Mediated Rejection: What’s new?
Current therapeutic developments include the management of pre-sensitized
patients before transplant and treating AMR. There are several off-label drugs now
being used to treat these patients. Eculizumab, imlifidase, and interleukin-6 (IL-6)
inhibitors are medications where there is now data to demonstrate efficacy. The
safety and effectiveness of bortezomib are suboptimal for desensitization and
treatment. In a small single-center study, eculizumab was shown to prevent AMR
after a heart transplant with a lower incidence of biopsy-proven AMR.32 However,
there was no difference in study outcomes or survival.32 Imlifidase is a new drug
approved for kidney transplantation that has shown promise in a few small studies.
So far, eculizumab and imflidase appear to provide a good risk/benefit ratio for
desensitization. Anti-IL-6 therapies are promising for AMR treatment. The
treatment of AMR with cytokine IL-6 blockade was developed as an autoimmune
treatment and used in kidney transplantation.33 Therapeutic strategies are lacking,
although repurposing antibodies developed for other diseases provides
encouraging results. Despite these advancements, AMR remains a clinical
challenge after heart transplantation.

Flow Cytometric Crossmatch Assay to Identify Recipient IgG Subtype
Antibodies
Human immunoglobulin G (IgG) is composed of two heavy and light chains linked
together by interchain disulfide bonds, which are responsible for forming threedimensional loops and the compact, domain-like structure of the molecule.
Complement activation is triggered by binding immunoglobulin. The hinge region
of IgG1 and IgG3 are very flexible and can efficiently bind complement, whereas
IgG2 and IgG4 are less flexible and bind complement less efficiently. Single
antigen bead testing is the gold standard for identifying donor-specific antibodies,
and mean fluorescence intensity is the report generated. Importantly, all donorspecific antibodies are not equal in terms of risk. A standard flow crossmatch in the
presence of donor-specific antibodies will be positive because it tests the reaction
of IgG 1-4 as a group. It is uncertain if knowing the IgG subclass or binding
complement ability is clinically useful. Indeed, transplants can be done safely
despite a positive flow crossmatch if the offending IgG is 2 or 4, not 1 or 3. The
New Jersey Organ and Tissue Sharing Network Lab developed a patented flow
crossmatch methodology allowing the immunologist to determine the subclass of
the donor-specific antibody. The information from this crossmatch can be
correlated with a CD3 antibody assessment and provide a real-time picture of the
risk of acute and accelerated AMR. With this testing, it is hypothesized that
approximately 380 more heart transplants could be done nationally.
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Monitoring for Acute Rejection: is there a role left for the heart
biopsy?
In 2006, it was reported that over 50% of transplant centers were performing
biopsy surveillance greater than ten years after the transplant.34 Genomic-based
rejection monitoring has since been developed. The proportion of positive allcause biopsies with ACR dating back to 1997 has been studied. The yield of
positive biopsies was much higher for clinically driven biopsies versus routine
surveillance biopsies. More recent studies have shown that the proportion of
treatable ACR by biopsy is less than 2%.31 AMR is prevalent, difficult to treat, and
can lead to graft dysfunction and allograft vasculopathy. There is a strong
correlation between the presence of pathologic AMR and cardiovascular
mortality.35 De-novo, class II donor-specific antibodies predict AMR and graft loss
and can be used to risk stratify patients. The current role of endomyocardial biopsy
is to evaluate graft dysfunction to differentiate causes, guide the intensity of
immunotherapy, and exclude rejection in patients with symptoms of graft
dysfunction or abnormal noninvasive testing. Routine surveillance heart biopsies in
asymptomatic patients are being gradually phased out in favor of clinical and noninvasive surveillance using biomarkers such as donor-derived cell-free DNA.

Noninvasive Surveillance After Heart Transplantation
Much progress has been made in the quest for noninvasive ways to assess
graft health after transplant. There is now better outcomes management
with fewer and better-targeted biopsies and fewer procedural complications.
In the United States, there are two assays used for noninvasive surveillance
of acute rejection: gene expression profiling (GEP, AlloMap) for determining
immune activation and donor-derived cell-free DNA (dd-cfDNA) for
assessing graft injury (AlloSure). Gene expression signatures of immune
activation and leukocyte trafficking are detectable and can be compared to
the rejection status of the allograft. A test was developed from 11 genes
that had differentially expressed profiles in the setting of acute rejection. 36
An algorithm can quantify the gene expression and produce a classifier
score of 1 to 40, with the higher numbers associated with acute rejection. In
the IMAGE study, the primary outcome was not different between groups
monitored for rejection using biopsy or GEP.37 The limitations of the
AlloMap GEP testing include a low positive predictive value and a lack of
validation for AMR; it is also affected by several clinical factors. AlloSure
detects both ACR and AMR; it is a valuable indicator of acute rejection and
a sensitive marker of graft injury.38 The dd-cfDNA levels may be
significantly elevated up to 5 months before the rejection event.39 AlloMap
GEP test can be used at 55 days post-transplant, and AlloSure can be used
starting at one month. Many biopsies have been eliminated with safe and
effective heart transplant surveillance.
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Heart Transplantation: Best Outcomes without Losing Patients on the
Waiting List
A paradox in heart transplantation in the United States is that the donor allocation
is based solely on the risk of waitlist mortality. Still, the Scientific Registry of
Transplant Recipients (SRTR) assessment of results is primarily based on posttransplant survival. The biggest change in donor characteristics in recent years is
the number of donors experiencing anoxic brain death from a drug overdose,
which is now almost 25% of all donors. The number of donors has increased for
those with a history of cocaine and other drug use, diabetes, and hypertension.
The use of donors with an LVEF <50% has decreased. There has been a steady
decline in waitlist mortality for all age groups, with those over 65 years having the
highest mortality.40 The donor allocation system in the United States changed in
2018, resulting in most transplants being status 1 and 2 patients. Recent data from
the ISHLT shows that donors over 50 years and ischemic time over 4 hours are
associated with the lowest survival rates at one year. Recent changes in transplant
recipient characteristics include increasing age and body mass index—both factors
are associated with higher 1-year mortality risk.41 A recent publication presents
information that questions the currently used modeling for transplant outcomes.42
In the United States, perhaps the focus should be on post-transplant survival and
not waitlist mortality.

Frailty and Patient Selection for LVAD or Transplant
Frailty is a complex state of increased vulnerability to physiologic stress distinct
from aging, comorbidity, and disability. Individuals develop a state of physical
decline that is out of proportion to their chronic illness. While there are more than
20 tools and assessments to evaluate frailty, no gold standard assessment exists.
A measure of frailty for advanced heart failure is needed. Such a tool should be
validated and measure typical features of frailty. Importantly, it should assist in
distinguishing heart failure-related debility vs. frailty-related debility. The measure
should help to predict clinical outcomes after LVAD implantation and determine if
the patient should undergo rehabilitation activities before implantation. Also, the
metric should be responsive to LVAD-reversible frailty. There are numerous
overlapping symptoms of frailty and heart failure, and these should be identified.
The Fried criteria for assessing frailty is extensively validated and includes
unintentional weight loss, exhaustion, low physical activity, gait speed, and hand
grip strength. In a study of patients with LVADs, the Fried criteria did not predict
survival; however, exhaustion, inactivity, and grip strength did predict >30-day
hospitalization. The Essential Frailty Toolset uses multiple measures of frailty and
is an excellent predictor of morbidity and mortality in cardiac surgical patients.43
While there is a lack of consensus on which assessment tools to use, working
groups are paying increased attention to the importance of frailty.
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Cardiac Xenotransplantation Update
The main problem in allotransplantation is the growing shortage of acceptable
donors. Multiple measures can be taken to enhance the number of donors, such
as policy changes from opt in to opt out, accepting sicker and older donors,
expanding the donor pool to include donations after circulatory death, and using
novel preservation techniques to increase the ex-vivo time of donor hearts - but
none have had a significant impact. Genetically modifying suitable animal organs
for transplantation in humans (xenotransplantation) to mitigate the organ shortage
problem is the core idea behind xenotransplantation. A recent breakthrough in
xenotransplantation occurred in 2016, where an immunological cardiac xenograft
was transplanted heterotopically (n=5) from pigs to baboons with a survival rate of
up to 945 days.44 With immunosuppressive therapy, there were no signs of
rejection in these animals. In 2018, five orthotopic (ie, life-supporting) porcine
cardiac xenografts were transplanted with the same genetic modification into
baboons. These baboons survived consistently up to 195 days with life supporting
porcine hearts.45 With adjusted immunosuppression, there were no signs of
rejection. Three fundamental changes to existing protocols are believed to be key
to this success. Firstly, to avoid primary xenograft dysfunction, which was
previously observed in up to 60% of porcine cardiac xenografts, a novel perfusion
system using continuous oxygenated hyperoncotic cold cardioplegic solution with
red blood cells, albumin, nutrition, and hormones was used, thus able to avoid
primary xenograft dysfunction. Then it was necessary to prevent cardiac xenograft
overgrowth, which was achieved with m-TOR pathway inhibitor rapamycin.
Zoonotic infections present another challenge, as pathogen-free pigs must be
used as donors - specifically free of PERV-C and porcine cytomegalovirus. Current
research includes expanded genetic modification, adapted immunosuppression,
and prevention of zoonotic infections, which will be validated in studies with 6month survival follow-up. Clinical trials may then be undertaken in patients needing
a re-transplant who are highly sensitized, older, have an allotransplantation
contraindication, or have a VAD contraindication.
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